James William Rogers Sells 11,529 Shares of Tempus AI (NASDAQ:TEM) Stock

Posted by Stanley Muller on Jul 2nd, 2026

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CFO James William Rogers sold 11,529 shares of Tempus AI stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the transaction, the chief financial officer owned 114,866 shares in the company, valued at approximately $6,317,630. This trade represents a 9.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James William Rogers also recently made the following trade(s):

On Tuesday, May 19th, James William Rogers sold 10,853 shares of Tempus AI stock. The stock was sold at an average price of $44.07, for a total value of $478,291.71.

Tempus AI Trading Up 6.3%

Shares of TEM opened at $61.60 on Thursday. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The firm has a market capitalization of $11.06 billion, a P/E ratio of -35.81 and a beta of 3.45. The stock’s fifty day simple moving average is $50.28 and its 200 day simple moving average is $54.60. Tempus AI, Inc. has a twelve month low of $41.73 and a twelve month high of $104.32.

Tempus AI (NASDAQ:TEM – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The firm had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.24) earnings per share. On average, equities research analysts forecast that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on TEM. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. HC Wainwright reduced their price target on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. BTIG Research reissued a “buy” rating and issued a $80.00 price objective on shares of Tempus AI in a research report on Monday, June 1st. Finally, Guggenheim cut their target price on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $68.54.

View Our Latest Report on TEM

Institutional Investors Weigh In On Tempus AI

A number of large investors have recently modified their holdings of TEM. Vanguard Group Inc. raised its holdings in shares of Tempus AI by 8.7% during the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after buying an additional 817,014 shares during the period. ARK Investment Management LLC boosted its holdings in Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after acquiring an additional 381,816 shares during the period. GC Wealth Management RIA LLC purchased a new position in Tempus AI in the 4th quarter worth approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. grew its position in Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after acquiring an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. grew its position in Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after acquiring an additional 821,490 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

Positive Sentiment: Analyst-style coverage argued Tempus AI remains attractive because of diagnostics momentum, AI platform expansion, and recent FDA-related product gains that may broaden future growth. Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion
Positive Sentiment: Some market commentary suggested the recent pullback may be creating a buying opportunity for investors who believe in Tempus AI’s long-term growth story. Tempus AI stock faces a make-or-break moment after its recent pullback
Neutral Sentiment: Konica Minolta completed the sale of Tempus shares it previously received, which may remove a supply overhang but is not an operating update. Konica Minolta Completes Sale of Tempus Shares to Bolster Balance Sheet
Negative Sentiment: Biovica said it is refocusing its U.S. commercial strategy and terminating its agreement with Tempus AI, which could reduce a partnership-related opportunity. Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI
Negative Sentiment: Recent insider selling by the CFO, CEO, and a director may be pressuring sentiment, even though the trades were made under pre-arranged plans. Tempus AI CEO insider sale filing

Tempus AI Company Profile

(Get Free Report)

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.